Publications by authors named "M Protopapa"

Background/objectives: Despite being widely promoted, protein supplementation's overall effectiveness during demanding basketball schedules remains unclear. This study investigated whether increased protein intake can accelerate recovery of muscle function during a 6-day congested basketball microcycle consisting of three consecutive games while accounting for the impact of playing time.

Methods: In a randomized, two-trial, cross-over, double-blind repeated measures design, eighteen male basketball players were assigned to a high (High PT) or a moderate (Mod PT) playing time group and participated in two trials, receiving daily either milk protein (PRO trial) or an isoenergetic amount of carbohydrates.

View Article and Find Full Text PDF

The purpose of this study was to compare the internal and external load in continuous and intermittent small-sided games (SSG) formats. Eight semi-professional soccer players participated in the study, and they completed three protocols: (a) I-intermittent SSG protocol (Int-I, 4 sets of 4 min with a 3 min recovery); (b) Continuous SSG protocol (Con, 2 sets of 8 min with a 3 min recovery); (c) II-SSG protocol (Int-II, 4 sets of 4 min, where each set includes 1 min of exercise with varying recovery periods (10, 20, 30 s), with a 3 min recovery period between sets). A one-way analysis of variance (ANOVA) was used to analyze the dependent variables, with significance determined at < 0.

View Article and Find Full Text PDF

Maturation is a key factor in sports participation and often determines the young athletes' characterization as a talent. However, there is no evidence of practical models for understanding the factors that discriminate children according to maturity. Hence, this study aims to deepen the understanding of the factors that affect maturity in 11-year-old Team Sports Athletes by utilizing explainable artificial intelligence (XAI) models.

View Article and Find Full Text PDF

Objective: We examined the impact of the rs10191329 genetic risk variant on neuroaxonal damage as measured by serum neurofilament light chain (sNfL) levels, and disability progression in people with multiple sclerosis (pwMS).

Methods: In a cohort of pwMS (n = 740), 658 participants were prospectively monitored every 2 years for less than a decade while 82 of 740 pwMS were monitored retrospectively for up to 40 years. We investigated associations between rs10191329 variants and clinical outcome, including Expanded Disability Status Scale (EDSS), disability accrual (defined by EDSS-increase of at least 1.

View Article and Find Full Text PDF

Background: As B cell-depleting therapies in multiple sclerosis (MS) have gained significant importance in the last several years, their long-term safety profile is of considerable clinical interest. Late-onset neutropenia (LON) is a rare, but potentially severe, adverse event that was first described in patients with rheumatic disorders under therapy with rituximab. Ofatumumab was approved in 2021 for the treatment of relapsing-remitting multiple sclerosis (RRMS).

View Article and Find Full Text PDF